Literature DB >> 26669470

Personalizing Therapy in Idiopathic Pulmonary Fibrosis: A Glimpse of the Future?

Jonathan A Kropski1, William E Lawson1,2, Timothy S Blackwell1,2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26669470      PMCID： PMC4731727          DOI： 10.1164/rccm.201509-1789ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  17 in total

1.  A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group.

Authors:  G R Bernard; A P Wheeler; M M Arons; P E Morris; H L Paz; J A Russell; P E Wright
Journal:  Chest       Date:  1997-07       Impact factor: 9.410

2.  High-dose acetylcysteine in idiopathic pulmonary fibrosis.

Authors:  Maurits Demedts; Juergen Behr; Roland Buhl; Ulrich Costabel; Richard Dekhuijzen; Henk M Jansen; William MacNee; Michiel Thomeer; Benoit Wallaert; François Laurent; Andrew G Nicholson; Eric K Verbeken; Johny Verschakelen; Christopher D R Flower; Frédérique Capron; Stefano Petruzzelli; Paul De Vuyst; Jules M M van den Bosch; Eulogio Rodriguez-Becerra; Giuseppina Corvasce; Ida Lankhorst; Marco Sardina; Mauro Montanari
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

Review 3.  Personalized therapy for lung cancer.

Authors:  Andre L Moreira; Juliana Eng
Journal:  Chest       Date:  2014-12       Impact factor: 9.410

4.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Authors:  Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle
Journal:  N Engl J Med       Date:  2015-05-17       Impact factor: 91.245

5.  Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.

Authors:  Talmadge E King; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Phil Hormel; Lisa Lancaster; Paul W Noble; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Roland M du Bois
Journal:  Lancet       Date:  2009-06-29       Impact factor: 79.321

6.  Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study.

Authors:  Imre Noth; Yingze Zhang; Shwu-Fan Ma; Dan Nicolae; Naftali Kaminski; Joe G N Garcia; Carlos Flores; Mathew Barber; Yong Huang; Steven M Broderick; Michael S Wade; Pirro Hysi; Joseph Scuirba; Thomas J Richards; Brenda M Juan-Guardela; Rekha Vij; MeiLan K Han; Fernando J Martinez; Karl Kossen; Scott D Seiwert; Jason D Christie
Journal:  Lancet Respir Med       Date:  2013-04-17       Impact factor: 30.700

7.  TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.

Authors:  Justin M Oldham; Shwu-Fan Ma; Fernando J Martinez; Kevin J Anstrom; Ganesh Raghu; David A Schwartz; Eleanor Valenzi; Leah Witt; Cathryn Lee; Rekha Vij; Yong Huang; Mary E Strek; Imre Noth
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

8.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

9.  Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.

Authors:  Fernando J Martinez; Joao A de Andrade; Kevin J Anstrom; Talmadge E King; Ganesh Raghu
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245
View more
  1 in total

Review 1.  Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis.

Authors:  Robert Brownell; Naftali Kaminski; Prescott G Woodruff; Williamson Z Bradford; Luca Richeldi; Fernando J Martinez; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2016-06-01       Impact factor: 21.405
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.